Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis

Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce major adverse cardiovascular events (MACE) in type 2 diabetic (T2DM) patients. Pharmacological selectivity of these agents to SGLT2 over SGLT1 is highly variant, with unknown clinical relevance. Genetically reduced SGLT1—but not SGLT2...

Full description

Bibliographic Details
Main Authors:	Alex Ali Sayour, Attila Oláh, Mihály Ruppert, Bálint András Barta, Béla Merkely, Tamás Radovits
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-01-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-52331-w

Similar Items

Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure
by: Alex Ali Sayour, et al.
Published: (2021-07-01)

Balanced Intense Exercise Training Induces Atrial Oxidative Stress Counterbalanced by the Antioxidant System and Atrial Hypertrophy That Is Not Associated with Pathological Remodeling or Arrhythmogenicity
by: Attila Oláh, et al.
Published: (2021-03-01)

Myocardial work index: a marker of left ventricular contractility in pressure‐ or volume overload‐induced heart failure
by: Bálint Károly Lakatos, et al.
Published: (2021-06-01)

Sex Differences in Morphological and Functional Aspects of Exercise-Induced Cardiac Hypertrophy in a Rat Model
by: Attila Oláh, et al.
Published: (2019-07-01)

Pressure overload-induced systolic heart failure is associated with characteristic myocardial microRNA expression signature and post-transcriptional gene regulation in male rats
by: Mihály Ruppert, et al.
Published: (2023-09-01)

Inflammasome activation in end‐stage heart failure‐associated atrial fibrillation
by: Szilvia Kugler, et al.
Published: (2022-08-01)

Sex similarities and differences in the reverse and anti-remodeling effect of pressure unloading therapy in a rat model of aortic banding and debanding
by: Tímea Bálint, et al.
Published: (2024-12-01)

Long-Term PDE-5A Inhibition Improves Myofilament Function in Left and Right Ventricular Cardiomyocytes through Partially Different Mechanisms in Diabetic Rat Hearts
by: Beáta Bódi, et al.
Published: (2021-11-01)

Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy
by: Mihály Ruppert, et al.
Published: (2019-01-01)

IL-1β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH
by: Dániel Kucsera, et al.
Published: (2023-01-01)

Comirnaty-induced cardiopulmonary distress and other symptoms of complement-mediated pseudo-anaphylaxis in a hyperimmune pig model: Causal role of anti-PEG antibodies
by: Bálint András Barta, et al.
Published: (2024-08-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)

Cardiovascular Outcome of the SGLT2 Inhibitor in Acute Myocardial Infarction: A Meta-Analysis
by: Siqi Hu, et al.
Published: (2025-02-01)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024-10-01)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
by: Peng‐juan Ji, et al.
Published: (2023-04-01)

Automated T1 and T2 mapping segmentation on cardiovascular magnetic resonance imaging using deep learning
by: András Kalapos, et al.
Published: (2023-07-01)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
by: Anzhu Wang, et al.
Published: (2022-05-01)

SGLT2 Inhibitors for Nephrologists
by: Mufti Baleegh-ur-Raheem Mahmood, et al.
Published: (2022-06-01)

SGLT2 Inhibitors for Cardioprotection
by: Sulthan Al Rashid, et al.
Published: (2023-07-01)

Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors
by: Theodora M. Stougiannou, et al.
Published: (2024-04-01)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
by: Yuta Suzuki, et al.
Published: (2022-05-01)

Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes
by: LiGang Huang, et al.
Published: (2024-06-01)

SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
by: Thomas A. Mavrakanas, et al.
Published: (2023-09-01)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
by: Xiutian Chen, et al.
Published: (2023-11-01)

The Renal Effects of SGLT2 Inhibitors
by: Hanny Sawaf, et al.
Published: (2022-06-01)

Neuroprotective Effect of SGLT2 Inhibitors
by: Agnieszka Pawlos, et al.
Published: (2021-11-01)

Benefits of SGLT2 inhibitors in arrhythmias
by: Jinghan Gao, et al.
Published: (2022-10-01)

SGLT2 Inhibitor–Induced Sympathoinhibition
by: Lakshini Y. Herat, PhD, et al.
Published: (2020-02-01)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
by: Yu Jiang, et al.
Published: (2022-03-01)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
by: Victor Chien-Chia Wu, et al.
Published: (2022-09-01)

Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
by: Walter Masson, et al.
Published: (2021-08-01)

Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
by: Jui-Yi Chen, et al.
Published: (2023-10-01)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Zinan Zhao, et al.
Published: (2022-04-01)

Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors
by: Taeyoung Choi, et al.
Published: (2024-09-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

SGLT2 inhibitors: Beyond glycemic control
by: Irtiza Hasan, et al.
Published: (2024-03-01)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
by: Carmen Llorens-Cebrià, et al.
Published: (2022-01-01)

SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01)

Possible renoprotective mechanisms of SGLT2 inhibitors
by: Akira Nishiyama, et al.
Published: (2023-03-01)